甲状腺がん診断薬市場：タイプ、技術、エンドユーザー別-2025-2030年の世界予測

甲状腺がん診断薬市場は、2023年に2億4,488万米ドルと評価され、2024年には2億5,758万米ドルに達すると予測され、CAGR 5.67%で成長し、2030年には3億6,033万米ドルに達すると予測されています。

甲状腺がん診断薬には、甲状腺に影響を及ぼす悪性腫瘍である甲状腺がんを検出・診断するためのさまざまな医療ツールや手法が含まれます。この市場の範囲には、超音波などの画像診断技術、微細針吸引生検、血液検査、がん細胞や遺伝子マーカーの同定を目的とした分子検査などが含まれます。その必要性は、画像診断技術の使用の増加や意識の高まりといった要因によって、世界的に甲状腺がんの発生率が上昇していることに起因しています。治療の主な用途は、早期発見、再発のモニタリング、病院、診断研究所、がん研究センターにおける治療計画の指導など多岐にわたる。

主な成長要因としては、診断ツールの技術的進歩、高齢者人口の増加、甲状腺疾患の有病率の増加などが挙げられます。非侵襲的で費用対効果の高い診断技術の開拓は、特にヘルスケア・インフラが拡大する新興国市場において、大きな潜在機会を提供します。さらに、診断精度を高めるためのテクノロジー企業と医療機関の提携は、戦略的な成長の道筋を示しています。とはいえ、先進的な診断手技や機器のコストが高く、厳しい規制の枠組みも相まって、市場拡大の課題となっています。

この分野における今後の技術革新は、早期発見と進行モニタリングのための新規バイオマーカーの開発、AIを活用した診断プラットフォームの強化、遠隔医療や在宅検査ソリューションによるアクセシビリティの向上に焦点を当てることができます。個別化医療と精密診断の研究開発に投資することで、企業は様々な遺伝的背景を持つ患者の多様なニーズに応えることができます。市場力学は競争的でありながらダイナミックであり、デジタルヘルスとビッグデータ解析の統合による予測診断の改善にチャンスがあります。この市場を効果的にナビゲートするために、企業はヘルスケアプロバイダーとのパートナーシップを優先し、コスト削減戦略に注力し、早期診断の意義に関する認識を醸成し、その影響力を拡大すべきです。

市場力学：急速に進化する甲状腺がん診断薬市場における主要市場インサイトの解明

甲状腺がん診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の甲状腺がん患者の増加
  • 早期診断と治療への注目の高まり
  • 民間団体によるがん検診プログラムの増加
• 市場抑制要因
  • 診断費用の高さと副作用の可能性
• 市場機会
  • 業界各社による甲状腺がん検出の研究開発投資
  • がん診断技術の進歩
• 市場の課題
  • 医療従事者の不足

ポーターの5つの力甲状腺がん診断薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：甲状腺がん診断薬市場における外部からの影響の把握

外部マクロ環境要因は、甲状腺がん診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析甲状腺がん診断薬市場における競合情勢の把握

甲状腺がん診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス甲状腺がん診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、甲状腺がん診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨甲状腺がん診断薬市場における成功への道筋を描く

甲状腺がん診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で甲状腺がんの罹患率が増加
    • 早期診断と治療への重点化
    • 民間団体ががん検診プログラムを増加
  • 抑制要因
    • 診断コストが高く、副作用の可能性もある
  • 機会
    • 業界関係者による甲状腺がん検出の研究開発投資
    • がん診断技術の進歩
  • 課題
    • 医療従事者の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 甲状腺がん診断薬市場：タイプ別

• 濾胞がん
• 乳頭がん

第7章 甲状腺がん診断薬市場：技術別

• 生検
• 血液検査
• イメージング

第8章 甲状腺がん診断薬市場：エンドユーザー別

• がん診断センター
• 病院の検査室
• 調査機関

第9章 南北アメリカの甲状腺がん診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の甲状腺がん診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの甲状腺がん診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Biocare Medical LLC
• Biocartis Group NV
• bioMerieux SA
• EverlyWell, Inc.
• F. Hoffmann-La Roche AG
• Fortis Healthcare Ltd
• Illumina, Inc.
• Koninklijke Philips N.V.
• Leica Biosystems Nussloch GmbH
• Merck KGaA
• NeoGenomics Laboratories, Inc.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. THYROID CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. THYROID CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. THYROID CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. THYROID CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. THYROID CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. THYROID CANCER DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FOLLICULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PAPILLARY CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. THYROID CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. THYROID CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Thyroid Cancer Diagnostics Market was valued at USD 244.88 million in 2023, expected to reach USD 257.58 million in 2024, and is projected to grow at a CAGR of 5.67%, to USD 360.33 million by 2030.

Thyroid cancer diagnostics encompass a range of medical tools and methodologies to detect and diagnose thyroid cancer, a malignancy affecting the thyroid gland. This market's scope includes diagnostic imaging technologies such as ultrasound, fine needle aspiration biopsy, blood tests, and molecular testing aimed at identifying cancerous cells or genetic markers. The necessity stems from the rising incidence of thyroid cancer globally, driven by factors like increased use of imaging techniques and heightened awareness. Applications are manifold, including aiding in early-stage detection, monitoring recurrence, and guiding treatment plans across hospitals, diagnostic laboratories, and cancer research centers.

Key growth factors include technological advancements in diagnostic tools, a growing geriatric population, and the increasing prevalence of thyroid disorders. The development of non-invasive, cost-effective diagnostic techniques offers a significant potential opportunity, especially in emerging markets with expanding healthcare infrastructure. Furthermore, collaborations between technology firms and medical institutions to enhance diagnostic accuracy present strategic avenues for growth. Nevertheless, the high cost of advanced diagnostic procedures and equipment, coupled with stringent regulatory frameworks, pose challenges in market expansion.

Future innovation in the field can focus on developing novel biomarkers for early detection and progression monitoring, enhancing AI-driven diagnostic platforms, and improving accessibility through telemedicine and at-home testing solutions. By investing in R&D for personalized medicine and precision diagnostics, businesses can better cater to the diverse needs of patients with varying genetic backgrounds. The thyroid cancer diagnostics market is competitive yet dynamic, with opportunities in digital health and the integration of big data analytics to improve predictive diagnostics. To effectively navigate this market, companies should prioritize partnerships with healthcare providers, focus on cost-reduction strategies, and foster awareness on the significance of early diagnosis to expand their reach and impact.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thyroid Cancer Diagnostics Market

The Thyroid Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of thyroid cancer cases across the globe
  • Increasing focus on early diagnosis and treatment
  • Private organizations increasing cancer screening programs
• Market Restraints
  • High cost of diagnosis and possible side effects
• Market Opportunities
  • Thyroid cancer detection R&D investment by industry players
  • Advancements in cancer diagnostics technology
• Market Challenges
  • Shortage of medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the Thyroid Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thyroid Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thyroid Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thyroid Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thyroid Cancer Diagnostics Market

A detailed market share analysis in the Thyroid Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thyroid Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thyroid Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thyroid Cancer Diagnostics Market

A strategic analysis of the Thyroid Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thyroid Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Biocare Medical LLC, Biocartis Group NV, bioMerieux SA, EverlyWell, Inc., F. Hoffmann-La Roche AG, Fortis Healthcare Ltd, Illumina, Inc., Koninklijke Philips N.V., Leica Biosystems Nussloch GmbH, Merck KGaA, NeoGenomics Laboratories, Inc., Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Thyroid Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Follicular Carcinoma and Papillary Carcinoma.
• Based on Technique, market is studied across Biopsy, Blood Test, and Imaging.
• Based on End-user, market is studied across Cancer Diagnostic Centers, Hospital Laboratories, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of thyroid cancer cases across the globe
    • 5.1.1.2. Increasing focus on early diagnosis and treatment
    • 5.1.1.3. Private organizations increasing cancer screening programs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of diagnosis and possible side effects
  • 5.1.3. Opportunities
    • 5.1.3.1. Thyroid cancer detection R&D investment by industry players
    • 5.1.3.2. Advancements in cancer diagnostics technology
  • 5.1.4. Challenges
    • 5.1.4.1. Shortage of medical professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Thyroid Cancer Diagnostics Market, by Type

• 6.1. Introduction
• 6.2. Follicular Carcinoma
• 6.3. Papillary Carcinoma

7. Thyroid Cancer Diagnostics Market, by Technique

• 7.1. Introduction
• 7.2. Biopsy
• 7.3. Blood Test
• 7.4. Imaging

8. Thyroid Cancer Diagnostics Market, by End-user

• 8.1. Introduction
• 8.2. Cancer Diagnostic Centers
• 8.3. Hospital Laboratories
• 8.4. Research Institutes

9. Americas Thyroid Cancer Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Thyroid Cancer Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Thyroid Cancer Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. Bio-Rad Laboratories, Inc.
• 3. Biocare Medical LLC
• 4. Biocartis Group NV
• 5. bioMerieux SA
• 6. EverlyWell, Inc.
• 7. F. Hoffmann-La Roche AG
• 8. Fortis Healthcare Ltd
• 9. Illumina, Inc.
• 10. Koninklijke Philips N.V.
• 11. Leica Biosystems Nussloch GmbH
• 12. Merck KGaA
• 13. NeoGenomics Laboratories, Inc.
• 14. Siemens Healthcare GmbH
• 15. Thermo Fisher Scientific, Inc.